Published in Blood Weekly, November 27th, 2003
The study demonstrated significantly better suppression of hepatitis B virus (HBV) replication and normalization of ALT (a measure of liver disease) with telbivudine compared to lamivudine monotherapy. Additional analyses of the...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.